Alumis to Participate in Upcoming September Investor Conferences
Alumis schedules multiple September 2026 healthcare conference appearances with webcast access for investors and stakeholders.
Rhea-AI Summary
Alumis (ALMS) will participate in four healthcare investor conferences in September 2026, featuring fireside chats and a presentation accessible via webcast.
The company will appear at the Wells Fargo, Cantor, Morgan Stanley and Baird healthcare conferences between September 8 and 15, with live and replay webcasts available on its investor website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 01 | SLE trial results | Negative | -56.8% | Overall population missed primary and secondary endpoints despite positive IFNGS-high subgroup responses |
| Aug 13 | Second-quarter earnings | Neutral | +3.7% | Quarterly results included clinical progress, continued losses, and $502.3 million liquidity |
| Aug 10 | Psoriasis clinical data | Positive | -7.8% | Long-term psoriasis data reported 75% PASI 90 and 54% PASI 100 responses |
| May 14 | First-quarter earnings | Neutral | -7.2% | Psoriasis data supported planned NDA submission while revenue declined and losses continued |
| Mar 19 | Year-end earnings | Positive | -1.3% | Positive psoriasis results and $345.1 million offering preceded a 1.26% decline |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions were mixed, with positive or mixed announcements followed by declines in three of five events.
Key Terms
tyrosine kinase 2 inhibitors technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
- Wells Fargo 21st Annual Healthcare Conference
September 8-10, 2026, Boston, MA
Fireside chat: Tuesday, September 8, 2026 at 11:00 am ET
- Cantor Global Healthcare Conference
September 9-11, 2026, New York, NY
Fireside chat: Wednesday, September 9, 2026 at 2:10 pm ET
- Morgan Stanley Global Healthcare Conference
September 14-16, 2026, New York, NY
Fireside chat: Monday, September 14, 2026 at 7:45 am ET
- Baird 2026 Global Healthcare Conference
September 15, 2026, New York, NY
Presentation: Tuesday, September 15, 2026 at 10:15 am ET
To access the live webcasts please visit the “Events” page of the “Investors" section of the Alumis website. Webcast replays will be archived on the company's website for 90 days.
About Alumis
Alumis is a late-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, its central nervous system penetrant TYK2 inhibitor, with initial development focused on Parkinson’s disease and additional neuroinflammatory, neurodegenerative and peripheral immune-mediated disease indications under evaluation. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
When will Alumis (ALMS) present at the Wells Fargo 21st Annual Healthcare Conference in 2026?
Alumis is scheduled for a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026 at 11:00 am ET in Boston, Massachusetts.
What is Alumis' schedule at the Cantor Global Healthcare Conference in September 2026?
At the Cantor Global Healthcare Conference in New York, running September 9-11, 2026, Alumis will hold a fireside chat on Wednesday, September 9, 2026 at 2:10 pm ET.
When is Alumis' session at the Morgan Stanley Global Healthcare Conference 2026?
During the Morgan Stanley Global Healthcare Conference in New York, held September 14-16, 2026, Alumis will participate in a fireside chat on Monday, September 14, 2026 at 7:45 am ET.
On what date and time will Alumis present at the Baird 2026 Global Healthcare Conference?
Alumis is scheduled for a presentation at the Baird 2026 Global Healthcare Conference in New York on Tuesday, September 15, 2026 at 10:15 am ET.
How can investors access Alumis (ALMS) webcasts for the September 2026 conferences?
Live webcasts of Alumis’ conference appearances can be accessed via the “Events” page of the “Investors” section of the Alumis website. Webcast replays will be archived on the company’s site for 90 days.